1. Home
  2. TXG vs SYRE Comparison

TXG vs SYRE Comparison

Compare TXG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

N/A

Current Price

$69.75

Market Cap

8.5B

Sector

Industrials

ML Signal

N/A

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

N/A

Current Price

$90.43

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TXG
SYRE
Founded
2012
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
8.5B
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
TXG
SYRE
Price
$69.75
$90.43
Analyst Decision
Hold
Strong Buy
Analyst Count
15
12
Target Price
$20.25
$85.08
AVG Volume (30 Days)
2.5M
1.1M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
76.97
N/A
EPS
N/A
N/A
Revenue
$245,893,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
68.06
N/A
52 Week Low
$11.17
$14.51
52 Week High
$69.67
$110.18

Technical Indicators

Market Signals
Indicator
TXG
SYRE
Relative Strength Index (RSI) 65.66 42.01
Support Level $58.70 $82.83
Resistance Level N/A $105.09
Average True Range (ATR) 3.35 4.08
MACD -0.10 -0.58
Stochastic Oscillator 79.58 22.81

Price Performance

Historical Comparison
TXG
SYRE

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: